The most relevant result obtained in this study is represented by the proof of concept that the combined inhibition of NAMPT and CD73 indeed results in a significant reduction in NAD+ and NMN concentration in tumors in vivo (Figure 4), leading to a reduced tumor cell proliferation, increased necrotic tumor cell death and to a significant, albeit small, advantage in terms of survival (Figure 6). The gene discussed is NAMPT; the disease is neoplasm.